Q3 Net Loss Narrows to $31.4M as First Tracks Lays Out 2027 Data Calendar
TRAX has more than doubled off its 52-week low of $14.72.
Summary
First Tracks posted a Q3 net loss of $31.4 million, or $0.88 a share, versus $41.9 million a year earlier, with R&D down to $23.8 million from $33.3 million as rosnilimab and ANB032 spending fell. Cash and investments stood at $155.6 million on Sept. 30, and the $200 million private placement closed in October lifts pro forma cash to $343 million — funding well past the 2027 readouts. The pipeline calendar is the real content: Cohort 2 celiac mucosal-healing data now expected Q1 2027, EoE Phase 1b top-line Q3 2027, and Phase 2 starts in vitiligo plus one more indication in H1 2027, all building on the positive October Cohort 1 gluten-challenge results. Rosnilimab is the soft spot — management is only 'assessing strategic options' to advance it, which reads as deprioritized. Q1 2027 Cohort 2 data is the next binary event for the celiac thesis.
At the time of this announcement, TRAX was trading at $46.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.72 to $49.91. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.